| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.51M | 480K | 480K | 10.18M | 9.29M | 18.11M | 103.2K |
| Revenue Growth % | - | -0.68% | 0% | 20.2% | -0.09% | 0.95% | -0.99% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 1.51M | 480K | 480K | 10.18M | 9.29M | 18.11M | -823.04K |
| Gross Margin % | 1% | 1% | 1% | 1% | 1% | 1% | -7.97% |
| Gross Profit Growth % | - | -0.68% | 0% | 20.2% | -0.09% | 0.95% | -1.05% |
| Operating Expenses | 18.85M | 19.65M | 19.65M | 82.54M | 93.21M | 41.83M | 36.05M |
| OpEx % of Revenue | 12.47% | 40.94% | 40.94% | 8.11% | 10.03% | 2.31% | 349.35% |
| Selling, General & Admin | 2.77M | 3.44M | 3.44M | 14.44M | 11.87M | 8.67M | 7.27M |
| SG&A % of Revenue | 1.83% | 7.16% | 7.16% | 1.42% | 1.28% | 0.48% | 70.48% |
| Research & Development | 16.08M | 16.21M | 16.21M | 68.1M | 81.34M | 36.64M | 28.78M |
| R&D % of Revenue | 10.64% | 33.77% | 33.77% | 6.69% | 8.75% | 2.02% | 278.88% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -3.48M | 0 |
| Operating Income | -17.33M | -19.17M | -19.17M | -72.36M | -83.92M | -23.72M | -35.95M |
| Operating Margin % | -11.47% | -39.94% | -39.94% | -7.11% | -9.03% | -1.31% | -348.35% |
| Operating Income Growth % | - | -0.11% | 0% | -2.77% | -0.16% | 0.72% | -0.52% |
| EBITDA | -16.43M | -18.35M | -18.31M | -71.24M | -82.49M | -22.51M | -35.03M |
| EBITDA Margin % | -10.87% | -38.24% | -38.15% | -7% | -8.88% | -1.24% | -339.38% |
| EBITDA Growth % | - | -0.12% | 0% | -2.89% | -0.16% | 0.73% | -0.56% |
| D&A (Non-Cash Add-back) | 909K | 816.69K | 858.41K | 1.13M | 1.43M | 1.21M | 926.25K |
| EBIT | -15.18M | -16.29M | -42.2M | -71.11M | -78.82M | -16.15M | -32.59M |
| Net Interest Income | 619.63K | 784.58K | 427.12K | -287.6K | -315.82K | 3.18M | 2.95M |
| Interest Income | 710.71K | 922.68K | 629.29K | 76.17K | 377.5K | 4.28M | 3.8M |
| Interest Expense | 91.08K | 138.1K | 202.16K | 363.76K | 693.32K | 1.11M | 851.87K |
| Other Income/Expense | 2.07M | 2.74M | 754.38K | 887.77K | 4.41M | 6.46M | 2.51M |
| Pretax Income | -15.27M | -16.43M | -16.43M | -71.48M | -79.51M | -17.25M | -33.44M |
| Pretax Margin % | -10.1% | -34.23% | -34.23% | -7.02% | -8.56% | -0.95% | -324.03% |
| Income Tax | -547K | 0 | 3.16K | 1.7M | 459.06K | 1.69M | -17.55K |
| Effective Tax Rate % | 0.96% | 1.05% | 1% | 1.02% | 1.01% | 1.1% | 1% |
| Net Income | -14.72M | -17.29M | -16.44M | -73.18M | -79.97M | -18.95M | -33.42M |
| Net Margin % | -9.74% | -36.03% | -34.24% | -7.19% | -8.61% | -1.05% | -323.86% |
| Net Income Growth % | - | -0.17% | 0.05% | -3.45% | -0.09% | 0.76% | -0.76% |
| Net Income (Continuing) | -15.27M | -16.43M | -42.4M | -73.18M | -79.97M | -18.95M | -33.42M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.51 | -0.49 | -0.59 | -2.29 | -2.31 | -0.54 | -0.95 |
| EPS Growth % | - | 0.68% | -0.2% | -2.88% | -0.01% | 0.77% | -0.76% |
| EPS (Basic) | -1.51 | -0.49 | -0.59 | -2.29 | -2.31 | -0.55 | -0.95 |
| Diluted Shares Outstanding | 9.7M | 35.33M | 28.07M | 32.02M | 34.65M | 35.03M | 36.02M |
| Basic Shares Outstanding | 9.7M | 35.33M | 28.07M | 32.02M | 34.65M | 34.64M | 36.02M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 51.82M | 103.92M | 79.1M | 185.95M | 149.32M | 113.44M | 87.78M |
| Cash & Short-Term Investments | 49.06M | 100.53M | 75.15M | 174.39M | 143.76M | 109.93M | 85.19M |
| Cash Only | 16.06M | 92.53M | 75.15M | 174.39M | 143.76M | 109.93M | 85.19M |
| Short-Term Investments | 33M | 8M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.43M | 2.14M | 132.4K | 7.51M | 619.43K | 222.03K | 8.31K |
| Days Sales Outstanding | 345.44 | 1.63K | 100.68 | 269.27 | 24.33 | 4.47 | 29.39 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 2.49M | 3.78M | 2.7M | 527.71K |
| Total Non-Current Assets | 2.6M | 1.97M | 5.17M | 3.56M | 3.08M | 2.29M | 1.51M |
| Property, Plant & Equipment | 2.55M | 1.88M | 2.07M | 3.49M | 2.97M | 2.2M | 1.41M |
| Fixed Asset Turnover | 0.59x | 0.26x | 0.23x | 2.92x | 3.12x | 8.23x | 0.07x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 197.07K | 197.07K | 7.17M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -147.88K | -109.84K | -4.07M | 69.28K | 109.57K | 84.89K | 103.5K |
| Total Assets | 54.42M | 105.89M | 84.26M | 189.51M | 152.4M | 115.73M | 89.27M |
| Asset Turnover | 0.03x | 0.00x | 0.01x | 0.05x | 0.06x | 0.16x | 0.00x |
| Asset Growth % | - | 0.95% | -0.2% | 1.25% | -0.2% | -0.24% | -0.23% |
| Total Current Liabilities | 10.35M | 7.18M | 16.15M | 29.82M | 55.08M | 31.46M | 38.18M |
| Accounts Payable | 558.98K | 712.71K | 1.81M | 3.32M | 3.67M | 3.09M | 4.24M |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 2.33M | 1.04M | 5.02M | 4.5M | 13.62M | 8.4M | 17.79M |
| Deferred Revenue (Current) | 32.98K | 993.38K | 725.54K | 1000K | 1000K | 52.88K | 0 |
| Other Current Liabilities | 1.41M | 2.07M | 6.2M | 11.62M | 21.43M | 18.54M | 56.27K |
| Current Ratio | 5.01x | 14.47x | 4.90x | 6.24x | 2.71x | 3.61x | 2.30x |
| Quick Ratio | 5.01x | 14.47x | 4.90x | 6.24x | 2.71x | 3.61x | 2.30x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 85.1M | 155.72M | 157.51M | 3.13M | 14.23M | 13.71M | 559.64K |
| Long-Term Debt | 0 | 1.52M | 2.97M | 2.99M | 14.15M | 13.54M | 417.34K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 53.83K | 173.66K | 142.3K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 44.16K | 0 | 0 | 0 |
| Other Non-Current Liabilities | 85.1M | 154.2M | 154.54M | 94.11K | 28.72K | 0 | 0 |
| Total Liabilities | 95.44M | 162.9M | 173.65M | 32.95M | 69.31M | 45.17M | 38.74M |
| Total Debt | 2.33M | 2.56M | 7.98M | 7.49M | 27.97M | 22.31M | 18.49M |
| Net Debt | -13.73M | -89.98M | -67.17M | -166.9M | -115.79M | -87.63M | -66.7M |
| Debt / Equity | - | - | - | 0.05x | 0.34x | 0.32x | 0.37x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -190.31x | -138.81x | -94.82x | -198.93x | -121.04x | -21.41x | -42.20x |
| Total Equity | -41.03M | -57.01M | -89.39M | 156.56M | 83.09M | 70.56M | 50.52M |
| Equity Growth % | - | -0.39% | -0.57% | 2.75% | -0.47% | -0.15% | -0.28% |
| Book Value per Share | -4.23 | -1.61 | -3.19 | 4.89 | 2.40 | 2.01 | 1.40 |
| Total Shareholders' Equity | -41.03M | -57.01M | -89.39M | 156.56M | 83.09M | 70.56M | 50.52M |
| Common Stock | 1.52K | 1.52K | 1.89K | 5.63K | 5.5K | 5.55K | 5.89K |
| Retained Earnings | -46.83M | -63.26M | -105.66M | -178.83M | -258.81M | -277.75M | -311.18M |
| Treasury Stock | 78.55M | 147.41M | -7.17M | -619.61K | -4 | -4 | 0 |
| Accumulated OCI | -410.69K | -344.89K | -350.98K | -93.98K | -849.3K | -1.8M | -526.9K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.26M | -18.15M | -28.53M | -43.41M | -48.61M | -28.45M | -29.7M |
| Operating CF Margin % | -9.44% | -37.82% | -59.44% | -4.27% | -5.23% | -1.57% | -287.79% |
| Operating CF Growth % | - | -0.27% | -0.57% | -0.52% | -0.12% | 0.41% | -0.04% |
| Net Income | -15.27M | -16.43M | -42.4M | -73.18M | -79.97M | -18.95M | -33.42M |
| Depreciation & Amortization | 909K | 816.69K | 858.41K | 1.13M | 1.45M | 1.21M | 926.25K |
| Stock-Based Compensation | 126.54K | 611.71K | 10.13M | 18.68M | 10.52M | 7.27M | 4.91M |
| Deferred Taxes | 0 | 0 | 0 | 622.43K | -44.16K | 0 | 0 |
| Other Non-Cash Items | -547.85K | -1.23M | 645.02K | -9.95K | -2.5M | -1.44M | -222.24K |
| Working Capital Changes | 513.83K | -1.92M | 2.23M | 9.35M | 21.94M | -16.55M | -1.89M |
| Change in Receivables | 268.67K | -480K | 480K | -3M | 6.89M | 397.4K | 213.72K |
| Change in Inventory | 0 | -2.59M | 925.17K | 6.02M | 0 | 0 | 0 |
| Change in Payables | 389.12K | 153.74K | 1.1M | 1.51M | 344.51K | -572.37K | 1.15M |
| Cash from Investing | -29.51M | 24.86M | 7.07M | -2.51M | -686.05K | -77.36K | 1.11M |
| Capital Expenditures | -514.7K | -151.83K | -935.2K | -2.51M | -690.94K | -85.01K | -33.58K |
| CapEx % of Revenue | 0.34% | 0.32% | 1.95% | 0.25% | 0.07% | 0% | 0.33% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 5.17K | 25.01M | 7.93K | 0 | 4.89K | 7.66K | 169 |
| Cash from Financing | 51.06M | 69.69M | 4.44M | 145.36M | 17.82M | -5.37M | 3.77M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 50M | 459.8K | -580.6K | -1.37M | 323.21K | 5.5K | -137.3K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -14.78M | -18.31M | -29.46M | -45.92M | -49.3M | -28.54M | -29.73M |
| FCF Margin % | -9.78% | -38.14% | -61.39% | -4.51% | -5.31% | -1.58% | -288.11% |
| FCF Growth % | - | -0.24% | -0.61% | -0.56% | -0.07% | 0.42% | -0.04% |
| FCF per Share | -1.52 | -0.52 | -1.05 | -1.43 | -1.42 | -0.81 | -0.83 |
| FCF Conversion (FCF/Net Income) | 0.97x | 1.05x | 1.74x | 0.59x | 0.61x | 1.50x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 603.68K | 1.05M | 778.51K |
| Taxes Paid | 0 | 0 | 0 | 0 | 2.43M | 1.38M | 33.95K |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -217.89% | -66.74% | -24.66% | -55.21% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | -797.49% |
| Net Margin | -974.03% | -3602.89% | -3424.06% | -719.18% | -860.59% | -104.61% | -32386.45% |
| Debt / Equity | - | - | - | 0.05x | 0.34x | 0.32x | 0.37x |
| Interest Coverage | -190.31x | -138.81x | -94.82x | -198.93x | -121.04x | -21.41x | -42.20x |
| FCF Conversion | 0.97x | 1.05x | 1.74x | 0.59x | 0.61x | 1.50x | 0.89x |
| Revenue Growth | - | -68.24% | 0% | 2019.85% | -8.67% | 94.9% | -99.43% |
| 2020 | |
|---|---|
| Service | 398.88K |
| Service Growth | - |
| License | 225K |
| License Growth | - |
Adagene Inc. (ADAG) reported $0.1M in revenue for fiscal year 2024. This represents a 93% decrease from $1.5M in 2018.
Adagene Inc. (ADAG) saw revenue decline by 99.4% over the past year.
Adagene Inc. (ADAG) reported a net loss of $55.4M for fiscal year 2024.
Adagene Inc. (ADAG) has a return on equity (ROE) of -55.2%. Negative ROE indicates the company is unprofitable.
Adagene Inc. (ADAG) had negative free cash flow of $47.6M in fiscal year 2024, likely due to heavy capital investments.